Top

BMC Cancer

Published in:

Open Access 01-12-2015 | Research article

Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study

Authors: Viktor H Koelzer, Pia Herrmann, Inti Zlobec, Eva Karamitopoulou, Alessandro Lugli, Ulrike Stein

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

Metastasis of colorectal cancer (CRC) is directly linked to patient survival. We previously identified the novel gene Metastasis Associated in Colon Cancer 1 (MACC1) in CRC and demonstrated its importance as metastasis inducer and prognostic biomarker. Here, we investigate the geographic expression pattern of MACC1 in colorectal adenocarcinoma and tumor buds in correlation with clinicopathological and molecular features for improvement of survival prognosis.

Methods

We performed geographic MACC1 expression analysis in tumor center, invasive front and tumor buds on whole tissue sections of 187 well-characterized CRCs by immunohistochemistry. MACC1 expression in each geographic zone was analyzed with Mismatch repair (MMR)-status, BRAF/KRAS-mutations and CpG-island methylation.

Results

MACC1 was significantly overexpressed in tumor tissue as compared to normal mucosa (p < 0.001). Within colorectal adenocarcinomas, a significant increase of MACC1 from tumor center to front (p = 0.0012) was detected. MACC1 was highly overexpressed in 55% tumor budding cells. Independent of geographic location, MACC1 predicted advanced pT and pN-stages, high grade tumor budding, venous and lymphatic invasion (p < 0.05). High MACC1 expression at the invasive front was decisive for prediction of metastasis (p = 0.0223) and poor survival (p = 0.0217). The geographic pattern of MACC1 did not correlate with MMR-status, BRAF/KRAS-mutations or CpG-island methylation.

Conclusion

MACC1 is differentially expressed in CRC. At the invasive front, MACC1 expression predicts best aggressive clinicopathological features, tumor budding, metastasis formation and poor survival outcome.

Available only for authorised users

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMed

Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 2007;176:61–80.CrossRefPubMed

Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15(1):59–67.CrossRefPubMed

Pichorner A, Sack U, Kobelt D, Kelch I, Arlt F, Smith J, et al. In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted mice. Clin Exp Metastasis. 2012;29(6):573–83.CrossRefPubMed

Nitsche U, Rosenberg R, Balmert A, Schuster T, Slotta-Huspenina J, Herrmann P, et al. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surg. 2012;256(5):763–71. discussion 771.CrossRefPubMed

Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, et al. Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLoS One. 2012;7(11):e49249.CrossRefPubMedPubMedCentral

Guo T, Yang J, Yao J, Zhang Y, Da M, Duan Y. Expression of MACC1 and c-Met in human gastric cancer and its clinical significance. Cancer Cell Int. 2013;13(1):121.CrossRefPubMedPubMedCentral

Wang JJ, Hong Q, Hu CG, Fang YJ, Wang Y. [Significance of MACC1 protein expression in esophageal carcinoma]. Zhonghua yi xue za zhi. 2013;93(32):2584–6.PubMed

Wang G, Kang MX, Lu WJ, Chen Y, Zhang B, Wu YL. MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance. Oncol Lett. 2012;4(4):783–91.PubMedPubMedCentral

10.

Xie C, Wu J, Yun J, Lai J, Yuan Y, Gao Z, et al. MACC1 as a prognostic biomarker for early-stage and AFP-normal hepatocellular carcinoma. PLoS One. 2013;8(5):e64235.CrossRefPubMedPubMedCentral

11.

Gao S, Lin BY, Yang Z, Zheng ZY, Liu ZK, Wu LM, et al. Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation. Int J Med Sci. 2014;11(3):268–75.CrossRefPubMedPubMedCentral

12.

Ji D, Lu ZT, Li YQ, Liang ZY, Zhang PF, Li C, et al. MACC1 expression correlates with PFKFB2 and survival in hepatocellular carcinoma. Asian Pac J Cancer Prev. 2014;15(2):999–1003.CrossRefPubMed

13.

Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011;31(4):1141–5.PubMed

14.

Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg. 2011;141(4):895–8.CrossRefPubMed

15.

Wang Z, Li Z, Wu C, Wang Y, Xia Y, Chen L, et al. MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer. Med Oncol. 2014;31(1):790.CrossRefPubMed

16.

Sheng XJ, Li Z, Sun M, Wang ZH, Zhou DM, Li JQ, et al. MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET. Oncol Lett. 2014;8(2):891–7.PubMedPubMedCentral

17.

Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye C, et al. Overexpression of MACC1 and Its significance in human Breast Cancer Progression. Cell & Biosci. 2013;3(1):16.CrossRef

18.

Muendlein A, Hubalek M, Geller-Rhomberg S, Gasser K, Winder T, Drexel H, et al. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. Eur J Cancer. 2014;50(12):2134–41.CrossRefPubMed

19.

Hu H, Tian D, Chen T, Han R, Sun Y, Wu C. Metastasis-associated in colon cancer 1 is a novel survival-related biomarker for human patients with renal pelvis carcinoma. PLoS One. 2014;9(6):e100161.CrossRefPubMedPubMedCentral

20.

Meng F, Li H, Shi H, Yang Q, Zhang F, Yang Y, et al. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/beta-catenin signaling pathway. PLoS One. 2013;8(4):e60821.CrossRefPubMedPubMedCentral

21.

Yang T, Kong B, Kuang YQ, Cheng L, Gu JW, Zhang JH, et al. Overexpression of MACC1 protein and its clinical implications in patients with glioma. Tumour Biol. 2014;35(1):815–9.CrossRefPubMed

22.

Hagemann C, Fuchs S, Monoranu CM, Herrmann P, Smith J, Hohmann T, et al. Impact of MACC1 on human malignant glioma progression and patients’ unfavorable prognosis. Neuro Oncol. 2013;15(12):1696–709.CrossRefPubMedPubMedCentral

23.

Zhang K, Zhang Y, Zhu H, Xue N, Liu J, Shan C, et al. High expression of MACC1 predicts poor prognosis in patients with osteosarcoma. Tumour Biol. 2014;35(2):1343–50.CrossRefPubMed

24.

Stein U. MACC1 - a novel target for solid cancers. Expert Opin Ther Targets. 2013;17(9):1039–52.CrossRefPubMed

25.

Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44(5):697–705.CrossRefPubMed

26.

Karamitopoulou E, Zlobec I, Kolzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol. 2013;26(2):295–301.CrossRefPubMed

27.

Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012;10:51.CrossRefPubMedPubMedCentral

28.

Ruschoff J, Nagelmeier I, Baretton G, Dietel M, Hofler H, Schildhaus HU, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe. 2010;31(3):208–17.CrossRefPubMed

29.

Dawson H, Galvan JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, et al. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer J Int du Cancer. 2014;134(10):2342–51.CrossRef

30.

Perneger TV. What’s wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236–8.CrossRefPubMedPubMedCentral

31.

Staub E, Groene J, Heinze M, Mennerich D, Roepcke S, Klaman I, et al. Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors. Mol Cancer. 2007;6:79.CrossRefPubMedPubMedCentral

32.

Lips EH, van Eijk R, de Graaf EJ, Doornebosch PG, de Miranda NF, Oosting J, et al. Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res. 2008;14(3):772–81.CrossRefPubMed

33.

Zhen T, Dai S, Li H, Yang Y, Kang L, Shi H, et al. MACC1 promotes carcinogenesis of colorectal cancer via beta-catenin signaling pathway. Oncotarget. 2014;5(11):3756–69.CrossRefPubMedPubMedCentral

34.

Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98(18):10356–61.CrossRefPubMedPubMedCentral

35.

Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 2005;179(1–2):56–65.CrossRefPubMed

36.

Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1(7):651–61.CrossRefPubMedPubMedCentral

37.

Christofori G. New signals from the invasive front. Nature. 2006;441(7092):444–50.CrossRefPubMed

38.

Bosman FT. World Health Organization., International Agency for Research on Cancer.: WHO classification of tumours of the digestive system, 4th edn. Lyon: International Agency for Research on Cancer; 2010.

39.

Gao J, Ding F, Liu Q, Yao Y. Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem. 2013;376(1–2):21–32.CrossRefPubMed

40.

Wang L, Wu Y, Lin L, Liu P, Huang H, Liao W, et al. Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion. Int J Cancer J Int du Cancer. 2013;133(6):1419–30.CrossRef

41.

Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br J Cancer. 2013;108(10):2088–96.CrossRefPubMedPubMedCentral

42.

Dawson H, Koelzer VH, Karamitopoulou E, Economou M, Hammer C, Muller DE, et al. The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology. 2014;64(4):577–84.CrossRefPubMed

43.

Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. 2014;74(6):1857–69.CrossRefPubMed

44.

Mathias RA, Gopal SK, Simpson RJ. Contribution of cells undergoing epithelial-mesenchymal transition to the tumour microenvironment. J Proteomics. 2013;78:545–57.CrossRefPubMed

45.

Kin C, Kidess E, Poultsides GA, Visser BC, Jeffrey SS. Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev Mol Diagn. 2013;13(6):581–99.CrossRefPubMed

46.

Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259(4):735–43.CrossRefPubMedPubMedCentral

47.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.CrossRefPubMed

Title: Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study
Authors: Viktor H Koelzer
Pia Herrmann
Inti Zlobec
Eva Karamitopoulou
Alessandro Lugli
Ulrike Stein
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1150-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

A microRNA molecular modeling extension for prediction of colorectal cancer treatment

Oncology patients overwhelmingly support tissue banking

Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls

Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway

Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker

MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets

Keynote webinar | Spotlight on antibody–drug conjugates in cancer